Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients

Christelle Devader, Morgane Roulot, Sébastien Moréno, Alessandra Minelli, Marco Bortolomasi, Chiara Congiu, Massimo Gennarelli, Marc Borsotto, Catherine Heurteaux, Jean Mazella

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Despite intense research on mechanisms underlying the depressive pathophysiology, reliable biomarkers to assess antidepressant treatment response are still lacking. Since the sortilin-derived propeptide (PE) displays potent antidepressant activities and can be measured in the blood of rodents, we wondered whether in human its seric level can vary between patients affected by major depressive disorder (MDD) and healthy controls and after antidepressant treatment.

METHODS: By using a specific dosing method, characterized by structure-recognition analysis with various synthesized PE analogues, we conducted a translational study to test whether blood levels of PE are under pathophysiological regulation and could serve as biomarkers of the depression state.

RESULTS: The serum concentration of PE, a peptide displaying potent antidepressant activities in rodents, is decreased in patients affected by major depressive disorder (MDD) when compared to healthy non-psychiatric controls cohort (p=0.035). Interestingly, pharmacological antidepressant treatments restore normal PE levels.

LIMITATIONS: The limitation of the study concerns the relatively small patient samples that could negatively affect the likelihood that a nominally statistically significant finding actually reflects a true effect.

CONCLUSIONS: The longitudinal quantification of the serum PE concentration could assist psychiatrists in the diagnosis of antidepressant response efficacy, and the need to modify the therapeutic strategy.

Original languageEnglish
Number of pages5
JournalJournal of Affective Disorders
DOIs
Publication statusE-pub ahead of print - Nov 4 2016

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Serum
Rodentia
Biomarkers
Hematologic Tests
Therapeutics
Psychiatry
sortilin
Pharmacology
Depression
Peptides
Research

Keywords

  • Journal Article

Cite this

Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. / Devader, Christelle; Roulot, Morgane; Moréno, Sébastien; Minelli, Alessandra; Bortolomasi, Marco; Congiu, Chiara; Gennarelli, Massimo; Borsotto, Marc; Heurteaux, Catherine; Mazella, Jean.

In: Journal of Affective Disorders, 04.11.2016.

Research output: Contribution to journalArticle

Devader, C, Roulot, M, Moréno, S, Minelli, A, Bortolomasi, M, Congiu, C, Gennarelli, M, Borsotto, M, Heurteaux, C & Mazella, J 2016, 'Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients', Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2016.10.049
Devader, Christelle ; Roulot, Morgane ; Moréno, Sébastien ; Minelli, Alessandra ; Bortolomasi, Marco ; Congiu, Chiara ; Gennarelli, Massimo ; Borsotto, Marc ; Heurteaux, Catherine ; Mazella, Jean. / Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. In: Journal of Affective Disorders. 2016.
@article{3403aed1245347c581530b50d1d7d250,
title = "Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients",
abstract = "BACKGROUND: Despite intense research on mechanisms underlying the depressive pathophysiology, reliable biomarkers to assess antidepressant treatment response are still lacking. Since the sortilin-derived propeptide (PE) displays potent antidepressant activities and can be measured in the blood of rodents, we wondered whether in human its seric level can vary between patients affected by major depressive disorder (MDD) and healthy controls and after antidepressant treatment.METHODS: By using a specific dosing method, characterized by structure-recognition analysis with various synthesized PE analogues, we conducted a translational study to test whether blood levels of PE are under pathophysiological regulation and could serve as biomarkers of the depression state.RESULTS: The serum concentration of PE, a peptide displaying potent antidepressant activities in rodents, is decreased in patients affected by major depressive disorder (MDD) when compared to healthy non-psychiatric controls cohort (p=0.035). Interestingly, pharmacological antidepressant treatments restore normal PE levels.LIMITATIONS: The limitation of the study concerns the relatively small patient samples that could negatively affect the likelihood that a nominally statistically significant finding actually reflects a true effect.CONCLUSIONS: The longitudinal quantification of the serum PE concentration could assist psychiatrists in the diagnosis of antidepressant response efficacy, and the need to modify the therapeutic strategy.",
keywords = "Journal Article",
author = "Christelle Devader and Morgane Roulot and S{\'e}bastien Mor{\'e}no and Alessandra Minelli and Marco Bortolomasi and Chiara Congiu and Massimo Gennarelli and Marc Borsotto and Catherine Heurteaux and Jean Mazella",
note = "Copyright {\circledC} 2016 Elsevier B.V. All rights reserved.",
year = "2016",
month = "11",
day = "4",
doi = "10.1016/j.jad.2016.10.049",
language = "English",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients

AU - Devader, Christelle

AU - Roulot, Morgane

AU - Moréno, Sébastien

AU - Minelli, Alessandra

AU - Bortolomasi, Marco

AU - Congiu, Chiara

AU - Gennarelli, Massimo

AU - Borsotto, Marc

AU - Heurteaux, Catherine

AU - Mazella, Jean

N1 - Copyright © 2016 Elsevier B.V. All rights reserved.

PY - 2016/11/4

Y1 - 2016/11/4

N2 - BACKGROUND: Despite intense research on mechanisms underlying the depressive pathophysiology, reliable biomarkers to assess antidepressant treatment response are still lacking. Since the sortilin-derived propeptide (PE) displays potent antidepressant activities and can be measured in the blood of rodents, we wondered whether in human its seric level can vary between patients affected by major depressive disorder (MDD) and healthy controls and after antidepressant treatment.METHODS: By using a specific dosing method, characterized by structure-recognition analysis with various synthesized PE analogues, we conducted a translational study to test whether blood levels of PE are under pathophysiological regulation and could serve as biomarkers of the depression state.RESULTS: The serum concentration of PE, a peptide displaying potent antidepressant activities in rodents, is decreased in patients affected by major depressive disorder (MDD) when compared to healthy non-psychiatric controls cohort (p=0.035). Interestingly, pharmacological antidepressant treatments restore normal PE levels.LIMITATIONS: The limitation of the study concerns the relatively small patient samples that could negatively affect the likelihood that a nominally statistically significant finding actually reflects a true effect.CONCLUSIONS: The longitudinal quantification of the serum PE concentration could assist psychiatrists in the diagnosis of antidepressant response efficacy, and the need to modify the therapeutic strategy.

AB - BACKGROUND: Despite intense research on mechanisms underlying the depressive pathophysiology, reliable biomarkers to assess antidepressant treatment response are still lacking. Since the sortilin-derived propeptide (PE) displays potent antidepressant activities and can be measured in the blood of rodents, we wondered whether in human its seric level can vary between patients affected by major depressive disorder (MDD) and healthy controls and after antidepressant treatment.METHODS: By using a specific dosing method, characterized by structure-recognition analysis with various synthesized PE analogues, we conducted a translational study to test whether blood levels of PE are under pathophysiological regulation and could serve as biomarkers of the depression state.RESULTS: The serum concentration of PE, a peptide displaying potent antidepressant activities in rodents, is decreased in patients affected by major depressive disorder (MDD) when compared to healthy non-psychiatric controls cohort (p=0.035). Interestingly, pharmacological antidepressant treatments restore normal PE levels.LIMITATIONS: The limitation of the study concerns the relatively small patient samples that could negatively affect the likelihood that a nominally statistically significant finding actually reflects a true effect.CONCLUSIONS: The longitudinal quantification of the serum PE concentration could assist psychiatrists in the diagnosis of antidepressant response efficacy, and the need to modify the therapeutic strategy.

KW - Journal Article

U2 - 10.1016/j.jad.2016.10.049

DO - 10.1016/j.jad.2016.10.049

M3 - Article

C2 - 27838145

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -